TCGA-98-8023-01A-11R-2247-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_ALPHA_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- MYC_TARGETS_V2+0.410
- G2M_CHECKPOINT+0.390
- IL6_JAK_STAT3_SIGNALING+0.390
- E2F_TARGETS+0.340
- APICAL_SURFACE+0.320
- MYC_TARGETS_V1+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.360
- PROTEIN_SECRETION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- FATTY_ACID_METABOLISM-0.300
- HEME_METABOLISM-0.290
- ADIPOGENESIS-0.270
- XENOBIOTIC_METABOLISM-0.200
- BILE_ACID_METABOLISM-0.170
- PEROXISOME-0.170
- ESTROGEN_RESPONSE_EARLY-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.860 |
| 2 | C3L-04071 | — | cohortSQ1 | 0.855 |
| 3 | C3N-03093 | — | cohortA1 | 0.841 |
| 4 | BS_H1ZS5FMZ | high-grade glioma | — | 0.834 |
| 5 | TCGA-34-5239-01A-21R-1820-07 | — | cohortSQ1 | 0.816 |
| 6 | 02fde1b1-c95c-4d8f-b57b-355b55072108 | — | — | 0.815 |
| 7 | SRR4296104 | — | cohortA1 | 0.810 |
| 8 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.807 |
| 9 | SJEPD001514_D1.RNA-Seq | EPN | Supratentorial EPN | 0.806 |
| 10 | SRR650185 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |